Revenue segments as reported by the company.

Transcatheter Aortic Valve Replacement

Transcatheter Mitral and Tricuspid Therapies

Surgical Structural Heart

Critical Care

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative expenses

Research and development expenses

Intellectual property litigation expenses, net

Change in fair value of contingent consideration liabilities

Special charges

Restructuring expenses

Other operating expenses, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Edwards Lifesciences projects robust sales growth amidst market advancements

Edwards Lifesciences showcased strong sales growth and financial performance in Q4 2022. Despite challenges like FX impacts and spotty backlog, the company remains confident in its growth outlook. Encouraging opportunities lie in TMTT and Surgical Structural Heart segments for future expansion.

Edwards Lifesciences reports robust Q1 sales, eyes global expansion

Edwards Lifesciences delivered strong sales performance in Q1, driven by key product segments and global growth.
The company faces challenges in managing expenses and navigating competitive dynamics, particularly in Japan.
Opportunities lie in continued market growth, product innovation, and efficiency enhancements across operations.
Overall, Edwards Lifesciences remains well-positioned for growth and market leadership in the cardiovascular space.

Edwards Lifesciences exceeds Q2 expectations, raises full-year guidance

Edwards Lifesciences delivered strong Q2 results, raising full year guidance and highlighting growth in key segments. While facing challenges like seasonal impacts and market recovery issues, the company remains focused on innovation and market expansion.

Edwards Lifesciences excels in Q3, poised for diversified growth

Edwards Lifesciences delivered a strong Q3 performance with growth across key segments and a positive outlook for 2023.
The company's focus on innovation, differentiated sales strategies, and patient-centric initiatives position it well for future growth.
Challenges in pricing dynamics and market competition require strategic management, while opportunities in diverse therapies and patient activation initiatives offer avenues for expansion.
Overall, Edwards Lifesciences maintains a solid financial position, supported by a robust balance sheet and a commitment to long-term growth.

Edwards Lifesciences posts strong Q4 results, eyes global growth opportunities

Edwards Lifesciences' Q4 2023 performance reflects solid financial health and strategic investments for future growth. Despite facing challenges such as rising expenses and competitive pressures, the company is well-positioned to capitalize on opportunities through innovation and market expansion.

Edwards Lifesciences reports robust Q1 sales growth and outlook

Edwards Lifesciences shows strong sales growth across key segments and raises 2024 outlook.
Investments in transcatheter platforms and positive milestones drive sustainable growth.
Challenges include managing increased expenses and ensuring center readiness for new therapies.
Opportunities in AI implementation, patient care initiatives, and diversified growth potential.

Edwards Lifesciences reports strong Q3 performance and strategic growth focus

Edwards Lifesciences delivered robust Q3 results driven by TAVR and TMTT growth, showcasing resilience and innovation.
While facing challenges in certain markets like Japan, Edwards maintains a strong competitive position and strategic focus on long-term growth.
The company's acquisitions, product advancements, and maintained guidance reflect a commitment to expansion and market leadership.
With opportunities in innovation and global expansion, Edwards is poised for continued growth and success in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Hologic

Investors looking for stocks in the Medical - Instruments sector might want to consider either Hologic (HOLX) or Edwards Lifesciences (EW). But which of these two stocks offers value investors a better bang for their buck right now?

HOLX vs. EW: Which Stock Should Value Investors Buy Now?

NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient's annulus size or sex. These data were presented during the late-breaking clini.

Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR

Becton, Dickinson and Co.

Shares of Becton Dickinson (BDX) advanced close to 3% Monday as the maker of syringes and other medical devices announced it was buying the Critical Care product unit of Edwards Lifesciences (EW) for $4.2 billion in cash.

Becton Dickinson Buys Critical Care Unit From Edwards Lifesciences for $4.2B

Edwards Lifesciences stock rallied Monday on medtech giant Becton Dickinson's plan to buy a key division for $4.2 billion.

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

The buyer intends to fund deal with a combination of $1 billion in cash and $3.2 billion of new debt in a transaction that is one of its largest of many.

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash

Edwards Lifesciences on Monday said it has agreed to sell its Critical Care products unit to Becton Dickinson in an all-cash transaction valued at $4.2 billion.

Edwards Lifesciences to sell critical care products unit to Becton Dickinson for $4.2 bln

Shares of Edwards Lifesciences Corp. EW, -1.14% rallied 3% in premarket trading Monday, after the company announced an agreement to sell its critical care product group to Becton Dickinson & Co. BDX, +2.29% in a cash deal valued at $4.2 billion. Edwards said it plans to use the proceeds from the sale to fund investments for growth, such as in technologies for technologies for aortic, mitral, tricuspid and pulmonic patients, and in therapeutic areas for interventional heart failure.

Edwards Lifesciences to sell its critical care product group for $4.2 billion to Becton Dickinson

Combination unlocks new future value-creation opportunities and is expected to be immediately accretive to BD revenue growth, adjusted gross margin, adjusted operating margin and adjusted EPS Expands BD's portfolio of smart connected care solutions with complementary and broad set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline Critical Care to operate as a separate business unit within BD's Medical segment, based in Irvine, Calif. and led by Katie Szyman FRANKLIN LAKES, N.J.

BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader

IRVINE, CA--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care. Edwards will use the after-tax cash proceeds to fund strategic growth investments. The sale enhances Edwards' balance sheet flexibilit.

Edwards Lifesciences to Sell Critical Care to BD

Investors are optimistic about Edward Lifesciences (EW), led by the strong performance of its SAPIEN 3 Ultra RESILIA platform and strong solvency.

Here's Why You Should Retain Edward Lifesciences (EW) for Now

U.S. heart valve maker Edwards Lifesciences has been hit with an EU antitrust complaint by Indian rival Meril including for allegedly anti-competitive practices related to patents, a move that could bolster EU regulators' scrutiny of Edwards.

Edwards Lifesciences hit with Meril's EU antitrust complaint

NYON, Switzerland--(BUSINESS WIRE)--Edwards Lifesciences today announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company's breakthrough RESILIA tissue technology, designed to extend the valve's durability.* Edwards' SAPIEN 3 Ultra RESILIA valve recently received CE Mark† for use in patients with heart valve disease due to native calcific aortic stenosis at all levels of surgical risk or due to the failure of either a.

Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability

Alcon Inc. - Registered Shares

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Alcon (ALC) and Edwards Lifesciences (EW). But which of these two stocks presents investors with the better value opportunity right now?

ALC vs. EW: Which Stock Is the Better Value Option?

Here is how Edwards Lifesciences (EW) and SNDL Inc. (SNDL) have performed compared to their sector so far this year.

Is Edwards Lifesciences (EW) Outperforming Other Medical Stocks This Year?

The heavy selling pressure might have exhausted for Edwards Lifesciences (EW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -10.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Edwards Lifesciences (EW)

Explore how Edwards Lifesciences' (EW) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Investing in Edwards Lifesciences (EW)? Don't Miss Assessing Its International Revenue Trends

Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.

Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up

Edwards Lifesciences Corporation (NYSE:EW ) Q1 2024 Earnings Conference Call April 25, 2024 5:00 PM ET Company Participants Mark Wilterding - SVP & IR Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - Global Leader of TMTT Larry Wood - Group President of TAVR and Surgical Structural Heart Katie Szyman - Global Leader of Critical Care Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Matt Taylor - Jefferies Joanne Wuensch - Citi Matt Miksic - Barclays Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Research Philip Chickering - Deutsche Bank Richard Newitter - Truist Securities Danielle Antalffy - UBS Joshua Jennings - TD Cowen Operator Greetings, and welcome to the Edwards Lifesciences First Quarter 2024 Results. At this time, all participants are in a listen-only mode.

Edwards Lifesciences Corporation (EW) Q1 2024 Earnings Call Transcript

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Edwards Lifesciences (EW) Q1 Earnings: A Look at Key Metrics

Edwards Lifesciences (EW) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.62 per share a year ago.

Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates

Edwards Lifesciences Corp on Thursday reported upbeat first-quarter profit due to strong demand for its artificial heart valves and other medical devices.

Edwards Lifesciences first-quarter profit beats estimates on heart devices strength

Edwards Lifesciences stock was muted late Thursday after the company beat first-quarter calls and gave more color into a looming spinoff.

Edwards Lifesciences Nabs Quarterly Beat And Plans A 'Critical' Spinoff

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales grew 8% adjusted for billing days Q1 TMTT sales grew 75% Q1 EPS of $0.58; adjusted1 EPS of $0.66 Raising 2024 sales guidance to the high end of previous 8 to 10%1 range Raising full-year 2024 sales guidance for TMTT.

Edwards Lifesciences Reports First Quarter Results

Labcorp Holdings Inc

ResMed

Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.

Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?

Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

News for Edwards Lifesciences Stock (EW)